Applications deadline: 6th August.
Chairs: K. Scheinemann (CH); A. Attarbaschi (AT)
Host Chairs: A. Biondi (IT); A. Ferrari (IT); C. Rizzari (IT)
Aims, objectives and teaching format
The ESO Masterclass is a full immersion, clinical oriented event designed for paediatric oncologists with 3-4 years experience in oncology who would like to receive further training on the treatment of children tumours from a multidisciplinary point of view.
The programme exposes participants to a full spectrum of issues in paediatric oncology and to practice-oriented training.
The Masterclass is organized into:
- Plenary lectures on state-of-the-art clinical treatments with reference to clinical guidelines given by renowned international faculty.
- Interactive workshop on communication
- Clinical case presentations/tumour board simulation where each participant presents and discusses a case with an international faculty of top experts in each tumour type.
The Masterclass is divided into two educational parts:
- Pre-recorded online lectures
- In-person event
The online lectures are released before the in-person event to give each participant the opportunity to prepare themselves in their own time and at their own place.
The in-person event is held in the style of a 2-and-half-day ‘retreat’, giving participants the opportunity to begin building an international oncology network as well as the chance to interact with renowned faculty in an informal environment over a number of days.
The Masterclass is held entirely in English and fluency in English is necessary for admission.
• Bone tumours
• Central nervous system tumours
• Rare tumours
• Soft-tissue sarcoma
• Wilms’ tumour
The Masterclass will be held in English and translation will not be provided.
The Masterclass will take place at UnaHotels in Varese (Milan area), Italy.
A fee of:
- 300 EUR for participant working in High-Middle Income Countries *
- 200 EUR for participants working in Low-Middle income countries *
- Access to the course and its educational resources
- Accommodation for 3 nights at UnaHotels in Varese
- Group transfer from Malpensa airport to the Masterclass venue
- Meals according to the programme
The fee does not cover travel costs: these should be organized and paid by the participant.
A discount of 30 EUR is given to participants who are already ESCO members.
The registration fee for this event is a small contribution towards the cost for organising it, therefore it will not be refunded if a participant withdraws or is unable to attend, for whatever reason.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the online part + 100% of the in-person event). An online evaluation questionnaire and learning assessment test will need to be completed for both parts in order to get the certificate that will be sent by email.
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE). The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
ESCO - The ESO College
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enroll in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits.
Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.ESCO.org for more information on how to join ESCO.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY.
50 PARTICIPANTS WILL BE SELECTED.
Applications deadline: 6th August.
IDEAL PROFILE OF THE MASTERCLASS CANDIDATE
- Aged up to 40 years
- 2-3 years’ experience in peadiatric oncology
- Involvement in scientific activities and clinical trials
- Fluency in English
- From ESO’s geographical reach (LINK TO: https://www.eso.net/en/what-we-do/programmes/1-5021-1-)
Interested oncologists should apply online (at the top of this page) providing:
- Letter describing motivation for attending;
- Supporting letter from head of department or mentor;
- CV with list publications (if the list of publications is not provided, it will be assumed that no articles have been published)
- Clinical case (please, use the provided template below)
- Professional experience form (please, use the provided template below)
CLINICAL CASE PRESENTATION
During the in-person event all participants will have the chance to present a clinical case as a clinical grandround discussion to the faculty and participants. A template giving details of the clinical case you would like to present should be submitted with your application. Please provide a straightforward case found in your daily clinical practice - no uncommon or extremely rare cases. You should include
- Diagnostic considerations
- Results, follow-up
- At least three questions proposed for discussion with the faculty
If you are selected for the Masterclass, you will be asked to prepare a PowerPoint presentation of your case (max 10 slides). If we receive too many cases from one tumour group, we may ask you to change the case topic you submitted during your application. We kindly ask you to let us know your 2nd choice topic if your first choice cannot be accommodated.
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Clinical Case template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.
Andishe Attarbaschi, Saint Anna Children's Hospital, Dept. of Paediatrics, Vienna, AT
Maja Beck Popovic, Lausanne University Hospital CHUV, Pediatric Oncology – Neuroblastoma and Retinoblastoma Dpt., Lausanne, CH
Veronica Biassoni, INT - Istituto Nazionale Tumori, Paediatric Dpt., Milano, IT
Andrea Biondi, San Gerardo Hospital, University of Milano - M. Tettamanti Research Centre, Monza, IT
Gianni Bisogno, University of Padova, Dept. of Women's and Children's Health, Padova, IT
Francesco Ceppi, CHUV / Centre Hospitalier Universitaire Vaudois, Paediatric Dpt., Lausanne, CH
Uta Dirksen, University Hospital Essen, Dept. of Pediatrics III, Hematology/Oncology, Essen, DE
François Doz, Institut Curie, Paediatric Oncology Dpt., Paris, FR
Angelika Eggert, Charité University Medicine Berlin, Dept. of Paediatric Oncology/ Haematology, Berlin, DE
Andrea Ferrari, Fondazione IRCCS Istituto Nazionale dei Tumori, Div. di Oncologia Pediatrica, Milano, IT
Norbert Graf, Saarland University Hospital (UKS), Dept. for Pediatric Oncology and Hematology, Homberg, DE
Jacques Grill, Institut Gustave Roussy, Dept. of Paediatric and Adolescent Oncology, Villejuif, FR
Darren Hargrave, Great Ormond Street Hospital, Department of Paediatric Oncology, London, UK
Henrik Hasle, Aarhus University Hospital, Dept. of Pediatrics, Aarhus N, DK
Roberto Luksch, Istituto Nazionale per lo Studio e la Cura dei Tumori, Paediatric Dpt., Milano, IT
Maura Massimino, National Cancer Institute - IRCCS Foundation, Pediatric Oncology Dept., Milano, IT
Christine Mauz-Körholz, Universitätsklinikum Giessen und Marburg, Dept. of Pediatric Hemotology and Oncology, Giessen, DE
Cristina Meazza, Istituto Nazionale per lo Studio e la Cura dei Tumori, Paediatric Oncology Dpt., Milano, IT
Hans Merks, Princess Maxima Center for Pediatric Oncology, Dept. of Pediatric Oncology, Utrech, NL
Bruce Morland, Birmingham Children's Hospital, Oncology Dpt., Birmingham, UK
Daniel Orbach, Curie Institute, Paediatrics, Adolescent, Young Adults SIREDO Center, Paris, FR
Carmelo Rizzari, MBBM Foundation, ASST Monza, Oncohematology, Monza, IT
Katrin Scheinemann, Stiftung Ostschweizer Kinderspital, St. Gallen, CH
Dominik Schneider, Klinik für Kinder- und Jugendmedizin, Klinikum Dortmund, Dortmund, DE
Martin Schrappe, University Medical Center Schleswig-Holstein, Campus Kiel, Dept. of General Pediatrics, Kiel, DE
Thorsten Simon, University Clinic Köln, Dept. of Pediatric Oncology and Hematology, Köln, DE
Filippo Spreafico, National Cancer Institute - IRCCS Foundation, Dept. of Medical Oncology and Hematology, Milano, IT